BR0209973A - Composição farmacêutica lìquida - Google Patents

Composição farmacêutica lìquida

Info

Publication number
BR0209973A
BR0209973A BR0209973-0A BR0209973A BR0209973A BR 0209973 A BR0209973 A BR 0209973A BR 0209973 A BR0209973 A BR 0209973A BR 0209973 A BR0209973 A BR 0209973A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pain
component
liquid
polyhydric alcohol
Prior art date
Application number
BR0209973-0A
Other languages
English (en)
Inventor
Neema Mahesh Kulkarni
Michael Schneider
Steven Bernard Silbering
Hans Richard Meyer-Wonnay
Nahid Sanii-Yahyai
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0209973(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0209973A publication Critical patent/BR0209973A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA LìQUIDA". A presente invenção refere-se a uma composição farmacêutica líquida de um análogo de GABA compreendendo, pelo menos, um álcool poliídrico contendo de 2 a 6 átomos de carbono possuindo um pH de cerca de 5,5 a 7,0 e adicionalmente uma composição farmacêutica líquida de dois componentes, compreendendo um primeiro componente compreendendo uma mistura em pó, compreendendo um análogo de GABA e um álcool poliídrico sólido, e um segundo componente compreendendo uma base líquida, assim como métodos de preparação das composições e um método de tratamento de doenças cerebrais, incluindo epilepsia, ataques de desfalecimento, hipocinesia, e traumatismos cranianos, distúrbios neurodegenerativos, depressão, mania e distúrbios bipolares, ansiedade, pânico, inflamação, cólica renal, insónia, dano gastrointestinal, incontinência, dor, incluindo dor neuropática, dor muscular, dor óssea, e enxaqueca utilizando uma quantidade terapeuticamente eficaz das composições farmacêuticas.
BR0209973-0A 2001-05-25 2002-04-29 Composição farmacêutica lìquida BR0209973A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25
PCT/IB2002/001500 WO2002094220A1 (en) 2001-05-25 2002-04-29 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR0209973A true BR0209973A (pt) 2004-04-06

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209973-0A BR0209973A (pt) 2001-05-25 2002-04-29 Composição farmacêutica lìquida

Country Status (44)

Country Link
US (2) US20020198261A1 (pt)
EP (1) EP1395242B1 (pt)
JP (1) JP2004534764A (pt)
KR (1) KR100582963B1 (pt)
CN (1) CN100346779C (pt)
AP (1) AP1815A (pt)
AR (1) AR033922A1 (pt)
AT (1) ATE334656T1 (pt)
AU (1) AU2002258026B2 (pt)
BG (1) BG108376A (pt)
BR (1) BR0209973A (pt)
CA (1) CA2446574C (pt)
CR (1) CR7150A (pt)
CY (1) CY1105147T1 (pt)
CZ (1) CZ299755B6 (pt)
DE (1) DE60213592T2 (pt)
DK (1) DK1395242T3 (pt)
DO (1) DOP2002000403A (pt)
EA (1) EA008087B1 (pt)
EE (1) EE200300587A (pt)
EG (1) EG24078A (pt)
ES (1) ES2265040T3 (pt)
GE (1) GEP20053620B (pt)
HK (1) HK1062646A1 (pt)
HR (1) HRP20030833B1 (pt)
HU (1) HUP0401366A2 (pt)
IL (1) IL158359A0 (pt)
IS (1) IS2428B (pt)
MA (1) MA27026A1 (pt)
MX (1) MXPA03009392A (pt)
MY (1) MY128615A (pt)
NO (1) NO20035200D0 (pt)
NZ (1) NZ529173A (pt)
OA (1) OA12604A (pt)
PA (1) PA8545901A1 (pt)
PE (1) PE20030087A1 (pt)
PL (1) PL366384A1 (pt)
PT (1) PT1395242E (pt)
RS (1) RS87203A (pt)
SI (1) SI1395242T1 (pt)
SK (1) SK286227B6 (pt)
SV (1) SV2003001053A (pt)
WO (1) WO2002094220A1 (pt)
ZA (1) ZA200308393B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0934061T1 (en) 1996-07-24 2003-10-31 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1545491A1 (en) * 2002-08-15 2005-06-29 Pfizer Limited Therapeutic use of fused bicyclic or tricyclic amino acids
CN101862317A (zh) * 2002-12-13 2010-10-20 沃尼尔·朗伯有限责任公司 用于治疗纤维肌痛和其它疾病的普加巴林衍生物
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PL376949A1 (pl) * 2002-12-20 2006-01-09 Dynogen Pharmaceuticals, Inc. Sposoby leczenia niebolesnych zaburzeń pęcherza moczowego przy użyciu modulatorów podjednostki Ó2Ű kanału wapniowego
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
EP1663398B1 (en) * 2003-09-12 2009-11-25 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
ATE526988T1 (de) * 2003-10-08 2011-10-15 Mallinckrodt Llc Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
KR100870381B1 (ko) * 2004-10-14 2008-11-25 다이킨 고교 가부시키가이샤 분위기개변방법, 그리고 이에 이용되는 분무제 및 분무장치
WO2007017510A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Isophthalsäurediamide zur behandlung der alzheimer erkrankung
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
US20230255885A1 (en) * 2018-08-18 2023-08-17 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
EP3836898A2 (en) 2018-08-18 2021-06-23 FTF Pharma Private Limited Pharmaceutical suspension for oral dosage
KR20210143874A (ko) 2019-03-26 2021-11-29 오리온 코포레이션 프레가발린 제형 및 이의 용도
US20240099989A1 (en) * 2021-02-05 2024-03-28 Kinki University Agent for preventing or improving peripheral neuropathy
CN118139617A (zh) * 2021-08-31 2024-06-04 艾维恩制药有限公司 稳定的加巴喷丁粉体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
BR9910508B1 (pt) * 1998-05-15 2012-01-24 preparações farmacêuticas estabilizadas de derivados de ácido gama-aminobutìrico.
PT1337271E (pt) * 2000-11-30 2005-01-31 Pfizer Prod Inc Combinacao de agonistas de gaba e inibidores de sorbitol desidrogenase

Also Published As

Publication number Publication date
SK286227B6 (sk) 2008-05-06
ATE334656T1 (de) 2006-08-15
IS2428B (is) 2008-10-15
IL158359A0 (en) 2004-05-12
AU2002258026B2 (en) 2007-08-02
US7256216B2 (en) 2007-08-14
NZ529173A (en) 2005-07-29
SI1395242T1 (en) 2006-10-31
EG24078A (en) 2008-05-11
AP1815A (en) 2008-01-04
GEP20053620B (en) 2005-09-26
CA2446574C (en) 2008-04-01
DK1395242T3 (da) 2006-10-30
HRP20030833A2 (en) 2004-08-31
SV2003001053A (es) 2003-03-18
PE20030087A1 (es) 2003-02-14
PL366384A1 (en) 2005-01-24
EP1395242A1 (en) 2004-03-10
RS87203A (en) 2006-10-27
CN1509165A (zh) 2004-06-30
NO20035200L (no) 2003-11-24
HUP0401366A2 (hu) 2004-11-29
HRP20030833B1 (en) 2007-04-30
CY1105147T1 (el) 2010-03-03
NO20035200D0 (no) 2003-11-24
CZ20033066A3 (cs) 2004-08-18
US20020198261A1 (en) 2002-12-26
MY128615A (en) 2007-02-28
MA27026A1 (fr) 2004-12-20
JP2004534764A (ja) 2004-11-18
US20040072904A1 (en) 2004-04-15
KR100582963B1 (ko) 2006-05-24
IS6986A (is) 2003-10-09
AR033922A1 (es) 2004-01-07
EE200300587A (et) 2004-02-16
WO2002094220A1 (en) 2002-11-28
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
SK14112003A3 (sk) 2004-08-03
DE60213592D1 (de) 2006-09-14
CA2446574A1 (en) 2002-11-28
EP1395242B1 (en) 2006-08-02
PA8545901A1 (es) 2003-09-05
ES2265040T3 (es) 2007-02-01
AP2003002907A0 (en) 2003-12-31
CZ299755B6 (cs) 2008-11-12
OA12604A (en) 2006-06-08
DOP2002000403A (es) 2002-11-30
HK1062646A1 (en) 2004-11-19
EA200301152A1 (ru) 2004-04-29
CR7150A (es) 2004-02-23
KR20040003006A (ko) 2004-01-07
BG108376A (bg) 2005-04-30
ZA200308393B (en) 2005-04-26
DE60213592T2 (de) 2007-08-09
EA008087B1 (ru) 2007-02-27
CN100346779C (zh) 2007-11-07

Similar Documents

Publication Publication Date Title
BR0209973A (pt) Composição farmacêutica lìquida
Pei A review of pharmacology and clinical use of piperine and its derivatives
Dana et al. The effect of cognitive and aerobic training on cognitive and motor function, and brain-derived neurotrophic factors in elderly men
IL176689A0 (en) Use of memantine for the preparation of a medicament for the treatment of mild and mild-to-moderate alzheimer's disease
UA49011C2 (uk) Похідні циклічної амінокислоти, фармацевтична композиція та спосіб лікування
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
CA2864606C (en) Methods of treating and preventing diseases and disorders of the central nervous system
DE60106026D1 (de) 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen
ES2285870T3 (es) Compuestos 1-(amino ciclico)-alquilciclohexano, composiciones farmaceuticas de los mismos y su uso como anticonvulsivos.
DE602006009976D1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
CN105209044A (zh) 用于疼痛病症的新的治疗性米氮平组合物
DE602006009848D1 (de) Die regeneration von neuronen des zentralen nervensystems stimulierende peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung
IL120006A0 (en) Valnoctamide stereoisomers a method for their separation and uses thereof
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта
WO2007139433A8 (en) Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application
ECSP034853A (es) Composición farmacéutica líquida
EP1321139B1 (en) 2-Indanylamino deratives for the therapy of chronic, acute or inflammatory pain
Raman et al. Parkinson’s Disease-A Review on Advances and Treatment Strategies
RU2120289C1 (ru) Способ лечения больных с неврологическими проявлениями остеохондроза позвоночника
BRPI0417797A (pt) soro sangüìneo biologicamente ativo, métodos para produzi-lo e seus usos
JP2022510363A (ja) （ｒ）－２－（２－オキソピロリジン－１－イル）ブタンアミドと（ｓ）－２－（２－オキソピロリジン－１－イル）ブタンアミドを非ラセミ比で含む相乗的組成物
RU2139712C1 (ru) Средство для воздействия на биологически активные точки и рефлексогенные зоны
UY27310A1 (es) Composición farmacéutica líquida
Nofzinger et al. Antidepressant effects on cerebral metabolism in depressed patients across waking and REM sleep:[18F]-FDG PET studies
JP2015503592A (ja) 神経成長因子の投与による疼痛処置方法

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.